Oral News and Research

RSS

FDA approves Watson's novel oral contraceptive

Watson Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approval of a novel oral contraceptive product – the first and only low dose oral contraceptive to combine 0.8 mg norethindrone and 0.025 mg ethinyl estradiol in chewable form, with four 75 mg ferrous fumarate (iron) placebo tablets. Taken orally, once daily, the product is proven effective in lowering the risk of pregnancy.

22 Dec 2010

New era for anticoagulant therapy

In a Guest Editorial published in the new publication Clinical Investigation, Dr Jeffrey Weitz and Dr John Eikelboom of McMaster University in Hamilton, Canada highlight the importance of the approval in October by the FDA of dabigatran etexilate (Pradaxa®; Boehringer Ingelheim). This new oral thrombin inhibitor provides an alternative to warfarin for long-term stroke prevention in patients with non-valvular atrial fibrillation.

22 Dec 2010

Edge releases edgeDMS for iPad for Dentists and Dental offices

Edge EHR Corp., EDGE, a provider of Dental Practice Management solutions for the Mac OS®, is pleased to announce the release of edgeDMS™ for iPad® for Dentists and Dental offices looking to leverage the awesome power of the Apple® iPad.

22 Dec 2010

Top ten advances in cardiovascular, stroke research in 2010

Research on reducing risks, improving medical treatment and improving lifestyle behaviors to fight the battle against heart disease and stroke are among the key scientific findings that make up this year's top cardiovascular and stroke research recognized by the American Heart Association/American Stroke Association.

22 Dec 2010

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Vertex Pharmaceuticals Incorporated today announced a modification of its Phase 2 clinical trial evaluating 12-week, response-guided regimens of its lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.

22 Dec 2010

Merrion, Novo Nordisk enter Collaboration and Option agreement for GIPET technology

Merrion Pharmaceuticals Plc, a publicly listed product development company, today announced the signing of a Collaboration and Option agreement with Novo Nordisk. The agreement will evaluate the ability of Merrion's patented GIPET® technology to boost the oral bioavailability of an undisclosed proprietary compound.

22 Dec 2010

Jazz Pharmaceutical receives USPTO patent for Xyrem oral solution

Jazz Pharmaceuticals, today announced that the United States Patent and Trademark Office has issued a patent related to Xyrem oral solution titled "Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy."

22 Dec 2010

Exercise and Vitamin D supplementation most effective in reducing fall among seniors

A systematic review of over 50 clinical trials finds that exercise and Vitamin D supplements are the best ways to reduce the risk of falling in people aged 65 and over. The review is published in the December 21 issue of Annals of Internal Medicine and was commissioned by the US Preventive Services Task Force.

22 Dec 2010

Tap water cancer chemical detected

A new analysis has revealed a potential carcinogen in the tap water of 31 U.S. cities and experts are looking for ways to reduce exposure of the communities. The chemical called hexavalent chromium, got public attention in the 2000 film “Erin Brockovich” and has been found to cause cancer in laboratory animals by the National Toxicology Program, part of the National Institutes of Health.

21 Dec 2010

The Children's Agenda delivered to California's incoming policymakers

Citing the state's failure to prioritize kids, a comprehensive plan addressing the systemic education and health problems undermining children's development was delivered to California's incoming policymakers today. Authored by Children Now, the state's leading multi-issue research and advocacy group for children, The Children's Agenda details the top ten, high-priority, high-impact actions California policymakers should take to reverse the declining status of children.

21 Dec 2010

Dentists recognized for excellence in ethics, leadership and professionalism

Two local dentists were recently recognized for excellence in ethics, leadership and professionalism when they were invited to become Fellows of the American College of Dentists.

21 Dec 2010

AmeriCares, Baxter team up to deliver IV solutions to prevent cholera outbreak in Haiti

AmeriCares and Baxter International Inc. have teamed to deliver additional lifesaving intravenous solutions to Haiti as part of their ongoing effort to stem the cholera outbreak. AmeriCares has been working around the clock to distribute IV solutions, oral rehydration salts, antibiotics, hand sanitizers and other critical aid since the outbreak was reported in October.

From Baxter International Inc. 21 Dec 2010

Emisphere, Novo Nordisk partner to develop and commercialize oral formulations of insulins

Emisphere Technologies, Inc. and Novo Nordisk A/S today announced that they have entered into an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's insulins, which have the potential of treating diabetes, using Emisphere's Eligen® Technology. This is the second license agreement between the two companies. The first agreement, for the development of oral formulations of GLP-1 receptor agonists, was signed in June 2008, with a potential drug currently in a Phase I clinical trial.

21 Dec 2010

Genzyme provides information on peak sale of alemtuzumab for multiple sclerosis

Genzyme Corporation today provided an extensive briefing on the market potential of alemtuzumab for multiple sclerosis at an event for investors and analysts in New York.

21 Dec 2010

Gilenya offers more benefits for MS therapy than previously realized

In September, patients suffering from multiple sclerosis (MS) received the welcome news that the U.S. Food and Drug Administration (FDA) had approved a promising new drug for their condition called Gilenya. Now, a team from The Scripps Research Institute has discovered that this drug's success may involve an unexpected biological mechanism acting within the central nervous system (CNS). This difference may mean that Gilenya offers even more benefits than previously realized and would represent the first MS therapy with direct CNS activities.

21 Dec 2010

Researchers develop new malaria vaccine strategy based on ingestion of genetically modified starch

Researchers from two laboratories in northern France have successfully vaccinated and protected mice by feeding them starch derived from green algae and genetically modified to carry vaccine proteins.

21 Dec 2010

Obstetrics and Gynecology: One third of pregnant women are not screened for gestational diabetes

Nearly one third of pregnant women are not being screened by a simple laboratory test for gestational diabetes mellitus (gestational diabetes), according to a study of more than 900,000 American women published online today in Obstetrics and Gynecology.

From Quest Diagnostics 21 Dec 2010

Robotic surgery as effective as other minimally invasive techniques for head and neck squamous cell carcinomas

Less-invasive robotic surgery for upper airway and digestive track malignant tumors is as effective as other minimally invasive surgical techniques based on patient function and survival, according to University of Alabama at Birmingham researchers.

21 Dec 2010

Aeterna Zentaris reaches agreement with FDA for Solorel SPA as a diagnostic test in AGHD

Aeterna Zentaris Inc. today announced that it has reached agreement with the Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for Solorel® (AEZS-130, macimorelin) which will enable the Company to complete the ongoing registration study required to gain approval as a diagnostic test for Adult Growth Hormone Deficiency (AGHD).

20 Dec 2010

Exciting progress made in MS research during 2010

Exciting advances were made in 2010 in virtually every field of MS research. Progress toward finding new therapies for MS is illustrated by the availability of the first oral disease-modifying therapy for MS. Progress was also made toward finding ways to restore function and improving quality of life and specific MS symptoms through exercise, meditation, rehabilitation and medications, including the first therapy specifically approved to treat a symptom of MS (Ampyra).

20 Dec 2010

Oral News and Research

FDA approves Watson's novel oral contraceptive

New era for anticoagulant therapy

Edge releases edgeDMS for iPad for Dentists and Dental offices

Top ten advances in cardiovascular, stroke research in 2010

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Merrion, Novo Nordisk enter Collaboration and Option agreement for GIPET technology

Jazz Pharmaceutical receives USPTO patent for Xyrem oral solution

Exercise and Vitamin D supplementation most effective in reducing fall among seniors

Tap water cancer chemical detected

The Children's Agenda delivered to California's incoming policymakers

Dentists recognized for excellence in ethics, leadership and professionalism

AmeriCares, Baxter team up to deliver IV solutions to prevent cholera outbreak in Haiti

Emisphere, Novo Nordisk partner to develop and commercialize oral formulations of insulins

Genzyme provides information on peak sale of alemtuzumab for multiple sclerosis

Gilenya offers more benefits for MS therapy than previously realized

Researchers develop new malaria vaccine strategy based on ingestion of genetically modified starch

Obstetrics and Gynecology: One third of pregnant women are not screened for gestational diabetes

Robotic surgery as effective as other minimally invasive techniques for head and neck squamous cell carcinomas

Aeterna Zentaris reaches agreement with FDA for Solorel SPA as a diagnostic test in AGHD

Exciting progress made in MS research during 2010

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News